Uncategorized
AstraZeneca Ends Manufacturing License at Indian Plant and Exits Site as Part of Global Strategy
AstraZeneca; India; manufacturing license; site exit; Bangalore plant; contract manufacturing; global strategy; pharmaceutical industry
AC Immune Narrows Pipeline and Cuts 30% Workforce to Extend Cash Runway
AC Immune; pipeline reduction; layoffs; cash runway; biotech; Alzheimer’s disease; Parkinson’s disease; late-stage assets; workforce reduction
Wave RNA Editing Restores Enzyme in Genetic Disorder but Fails to Impress Investors
Wave Life Sciences; RNA editing; AATD; alpha-1 antitrypsin deficiency; enzyme restoration; clinical trial; investor reaction; WVE-006
Treeline Announces $200M Funding Boost, Moves Three Cancer Drugs into Clinic
Treeline Biosciences; cancer drugs; clinical trials; TLN-121; TLN-372; TLN-254; BCL6 degrader; KRAS inhibitor; EZH2 inhibitor; Series A funding; lymphoma; solid tumors
Novartis Again Partners with Argo Biopharma in $5.2B+ RNAi Cardiovascular Deal
Novartis; Argo Biopharma; RNA interference (RNAi); siRNA; cardiovascular pipeline; ANGPTL3; dyslipidemia; biotech collaboration; drug development; milestone payments
FDA Announces New Rare Disease Approval Programme
FDA; rare disease; conditional approval pathway; accelerated approval; biologics; drug review; surrogate endpoints; real-world data; streamlined process
Gilead Unveils New Manufacturing Site in California as Part of $32B U.S. Investment Plan
Gilead Sciences; Foster City; California; manufacturing facility; biopharmaceuticals; $32 billion investment; economic impact; expansion; R&D; job creation; U.S. manufacturing
Wave Life Sciences Shares Dip After Mixed Data Update on GSK-Partnered AATD Therapy
Wave Life Sciences; GSK; AATD; RNA editing; WVE-006; clinical trial; protein levels; stock dip; biotech
Paul Offit, RFK Jr. Critic, Removed from Key FDA Vaccine Panel
Paul Offit; FDA; vaccine panel; RFK Jr.; removal; vaccine policy; VRBPAC; advisory committee; HHS
UK Pharma Trade Group Calls for Overhaul of Government’s Life Sciences Investment Evaluation and Medicines Pricing Schemes
UK life sciences; ABPI; VPAG; pharma trade group; investment evaluation; medicines pricing; government review; NHS; innovation; statutory scheme